Karyopharm Therapeutics (KPTI) Competitors $5.77 -0.39 (-6.33%) Closing price 04:00 PM EasternExtended Trading$5.78 +0.01 (+0.17%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. OGI, PRQR, HRTX, TRDA, CABA, ACRS, VTYX, TNXP, EPRX, and SCLXShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Organigram Global (OGI), ProQR Therapeutics (PRQR), Heron Therapeutics (HRTX), Entrada Therapeutics (TRDA), Cabaletta Bio (CABA), Aclaris Therapeutics (ACRS), Ventyx Biosciences (VTYX), Tonix Pharmaceuticals (TNXP), Eupraxia Pharmaceuticals (EPRX), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors Organigram Global ProQR Therapeutics Heron Therapeutics Entrada Therapeutics Cabaletta Bio Aclaris Therapeutics Ventyx Biosciences Tonix Pharmaceuticals Eupraxia Pharmaceuticals Scilex Karyopharm Therapeutics (NASDAQ:KPTI) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Which has preferable earnings & valuation, KPTI or OGI? Organigram Global has higher revenue and earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.34-$76.42M-$14.59-0.40Organigram Global$223.82M1.18-$33.39M$0.0539.20 Do analysts recommend KPTI or OGI? Karyopharm Therapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 489.25%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Organigram Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Organigram Global 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor KPTI or OGI? In the previous week, Karyopharm Therapeutics had 3 more articles in the media than Organigram Global. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 0 mentions for Organigram Global. Organigram Global's average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.14 indicating that Organigram Global is being referred to more favorably in the news media. Company Overall Sentiment Karyopharm Therapeutics Neutral Organigram Global Neutral Which has more volatility & risk, KPTI or OGI? Karyopharm Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Do institutionals & insiders hold more shares of KPTI or OGI? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 2.8% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is KPTI or OGI more profitable? Organigram Global has a net margin of 2.86% compared to Karyopharm Therapeutics' net margin of -90.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Organigram Global's return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-90.02% N/A -84.28% Organigram Global 2.86%-8.19%-5.79% SummaryOrganigram Global beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.03M$2.67B$6.10B$10.53BDividend YieldN/A53.56%5.51%4.67%P/E Ratio-0.4023.8685.6826.86Price / Sales0.34599.75583.23185.42Price / CashN/A28.3526.3031.10Price / Book-0.265.5913.256.72Net Income-$76.42M$32.78M$3.30B$276.44M7 Day Performance-11.77%5.24%4.70%3.13%1 Month Performance-12.58%10.88%8.43%10.21%1 Year Performance-55.79%-1.45%88.01%40.35% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.7744 of 5 stars$5.77-6.3%$34.00+489.3%-53.7%$50.03M$145.24M-0.40380OGIOrganigram Global1.0668 of 5 stars$1.97+16.6%N/A+5.1%$227.04M$117.47M39.41860High Trading VolumePRQRProQR Therapeutics2.3597 of 5 stars$2.19+3.8%$8.00+265.3%+21.0%$222M$20.46M-4.76180Positive NewsHRTXHeron Therapeutics3.5429 of 5 stars$1.27+5.0%$4.50+254.3%-36.8%$221.81M$144.29M-63.50300TRDAEntrada Therapeutics3.1273 of 5 stars$5.84+0.7%$25.67+339.5%-65.3%$220.62M$79.48M-3.28110CABACabaletta Bio2.641 of 5 stars$2.38+0.8%$14.50+509.2%-42.7%$215.86MN/A-0.8850Positive NewsACRSAclaris Therapeutics2.817 of 5 stars$1.92-3.5%$8.71+353.9%+59.7%$215.58M$18.72M-1.40100VTYXVentyx Biosciences1.6709 of 5 stars$3.03+1.7%$7.50+147.5%+77.6%$212.50MN/A-1.8030TNXPTonix Pharmaceuticals2.7924 of 5 stars$24.76+2.3%$70.00+182.7%+73.7%$212.22M$10.09M-0.6350EPRXEupraxia Pharmaceuticals3.0594 of 5 stars$5.77+0.4%$11.00+90.8%+125.3%$206.41MN/A-6.7829News CoverageAnalyst RevisionHigh Trading VolumeSCLXScilex2.3904 of 5 stars$26.62-8.9%$455.00+1,609.2%-51.0%$203.18M$56.59M-0.9280 Related Companies and Tools Related Companies Organigram Global Competitors ProQR Therapeutics Competitors Heron Therapeutics Competitors Entrada Therapeutics Competitors Cabaletta Bio Competitors Aclaris Therapeutics Competitors Ventyx Biosciences Competitors Tonix Pharmaceuticals Competitors Eupraxia Pharmaceuticals Competitors Scilex Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
